Jun. 16 at 12:46 PM
Edwards Lifesciences shares rose after the Centers for Medicare & Medicaid Services (CMS) released a proposed National Coverage Determination (NCD) memorandum for TAVR, a catalyst analysts had highlighted for months following Edwards' request that triggered the review process in December 2025. The proposal was largely favorable, expanding coverage to asymptomatic severe aortic stenosis patients under Coverage with Evidence Development, removing the dual-operator requirement, and eliminating several hospital volume restrictions that had limited procedure capacity.
Following the announcement, Leerink maintained its Market Perform rating and
$87 price target, describing the update as incrementally positive. The final NCD decision is expected before September 13, 2026, potentially providing another catalyst later this year.
$EW $SPY